Mind Medicine Due Diligence report.

Source: https://mindmed.co/
  • BlackRock.
  • Kevin O’leary.
  • Bruce Linton.
  • Credit Suisse Asset Management.
  • Mirae Asset Global Investments Co., Ltd.
  • The psychedelic market still faces considerable risk and uncertainties around securing U.S. FDA approvals and the stigma associated with the use of psychedelic drugs.
  • Mind Medicine’s unprofitability and increasing operational losses might affect its growth prospects.
  • The success rates of Phase 2 trials in Psychopharmacology are 24%. There might be a chance that none of Mind Medicine’s leading projects may pass.
  • ATAI Life Sciences. (ATAI).
  • Field Trip Psychedelics Inc. (FTRP)
  • Compass Pathaways. (CMPS)
  • Robert Barrow: CEO.
  • David D. Guebert: CFO.
  • Donald R. Gehlert: CSO.
  • Bradford Cross: CTO.



Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store
Oto Suvari

Oto Suvari

Heading up the group’s R&D activities for Hatchworks.